Back to News
Market Impact: 0.35
BlossomHill Q2 Loss Widens; BH-30643 Advances, Balance Sheet Strengthens
Source: Nasdaq
Healthcare & BiotechIPOs & SPACsCompany FundamentalsCorporate Guidance & Outlook
BlossomHill Therapeutics reported Q2 2026 results highlighting regulatory progress for BH-30643 and continued advancement of its oncology pipeline. The company also strengthened its balance sheet following a $168.3 million initial public offering, improving funding capacity for clinical and regulatory development.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
More News
- Warren Buffett stepping down as chairman of Berkshire Hathaway: 'Father Time always wins'
- American, United and Southwest are all cutting ‘marginal routes’ as jet fuel prices spike
- Exclusive-Anthropic considers releasing new AI model ahead of IPO, sources say
- Flock Offers Employees Buyouts as Customers Flee
- Anthropic selects Accenture as first embedded evaluator to help implement Amodei's slowdown proposal
- Anthropic’s first embedded evaluator is … Accenture?